OBJECTIVES: The purpose of the study was to assess the effects of maternal HIV-1 (human immunodeficiency virus) infection and vertically transmitted HIV-1 infection on the prevalence of congenital cardiovascular malformations in children. BACKGROUND: In the United States, an estimated 7000 children are born to HIV-infected women annually. Previous limited reports have suggested an increase in the prevalence of congenital cardiovascular malformations in vertically transmitted HIV-infected children. METHODS: In a prospective longitudinal multicenter study, diagnostic echocardiograms were performed at 4-6-month intervals on two cohorts of children exposed to maternal HIV-1 infection: 1) a Neonatal Cohort of 90 HIV-infected, 449 HIV-uninfected and 19 HIV-indeterminate children; and 2) an Older HIV-Infected Cohort of 201 children with vertically transmitted HIV-1 infection recruited after 28 days of age. RESULTS: In the Neonatal Cohort, 36 lesions were seen in 36 patients, yielding an overall congenital cardiovascular malformation prevalence of 6.5% (36/558), with a 8.9% (8/90) prevalence in HIV-infected children and a 5.6% (25/449) prevalence in HIV-uninfected children. Two children (2/558, 0.4%) had cyanotic lesions. In the Older HIV-Infected Cohort, there was a congenital cardiovascular malformation prevalence of 7.5% (15/201). The distribution of lesions did not differ significantly between the groups. CONCLUSIONS: There was no statistically significant difference in congenital cardiovascular malformation prevalence in HIV-infected versus HIV-uninfected children born to HIV-infected women. With the use of early screening echocardiography, rates of congenital cardiovascular malformations in both the HIV-infected and HIV-uninfected children were five- to ten-fold higher than rates reported in population-based epidemiologic studies but not higher than in normal populations similarly screened. Potentially important subclinical congenital cardiovascular malformations were detected.
OBJECTIVES: The purpose of the study was to assess the effects of maternal HIV-1 (human immunodeficiency virus) infection and vertically transmitted HIV-1 infection on the prevalence of congenital cardiovascular malformations in children. BACKGROUND: In the United States, an estimated 7000 children are born to HIV-infectedwomen annually. Previous limited reports have suggested an increase in the prevalence of congenital cardiovascular malformations in vertically transmitted HIV-infectedchildren. METHODS: In a prospective longitudinal multicenter study, diagnostic echocardiograms were performed at 4-6-month intervals on two cohorts of children exposed to maternal HIV-1 infection: 1) a Neonatal Cohort of 90 HIV-infected, 449 HIV-uninfected and 19 HIV-indeterminate children; and 2) an Older HIV-Infected Cohort of 201 children with vertically transmitted HIV-1 infection recruited after 28 days of age. RESULTS: In the Neonatal Cohort, 36 lesions were seen in 36 patients, yielding an overall congenital cardiovascular malformation prevalence of 6.5% (36/558), with a 8.9% (8/90) prevalence in HIV-infectedchildren and a 5.6% (25/449) prevalence in HIV-uninfectedchildren. Two children (2/558, 0.4%) had cyanotic lesions. In the Older HIV-Infected Cohort, there was a congenital cardiovascular malformation prevalence of 7.5% (15/201). The distribution of lesions did not differ significantly between the groups. CONCLUSIONS: There was no statistically significant difference in congenital cardiovascular malformation prevalence in HIV-infected versus HIV-uninfectedchildren born to HIV-infectedwomen. With the use of early screening echocardiography, rates of congenital cardiovascular malformations in both the HIV-infected and HIV-uninfectedchildren were five- to ten-fold higher than rates reported in population-based epidemiologic studies but not higher than in normal populations similarly screened. Potentially important subclinical congenital cardiovascular malformations were detected.
Authors: R Martin; P Boyer; H Hammill; H Peavy; A Platzker; R Settlage; A Shah; R Sperling; R Tuomala; M Wu Journal: J Pediatr Date: 1997-12 Impact factor: 4.406
Authors: C Rouzioux; D Costagliola; M Burgard; S Blanche; M J Mayaux; C Griscelli; A J Valleron Journal: Am J Epidemiol Date: 1995-12-15 Impact factor: 4.897
Authors: Susan B Brogly; Mark J Abzug; D Heather Watts; Coleen K Cunningham; Paige L Williams; James Oleske; Daniel Conway; Rhoda S Sperling; Hans Spiegel; Russell B Van Dyke Journal: Pediatr Infect Dis J Date: 2010-08 Impact factor: 2.129
Authors: T J Starc; S E Lipshultz; S Kaplan; K A Easley; J T Bricker; S D Colan; W W Lai; W M Gersony; G Sopko; D S Moodie; M D Schluchter Journal: Pediatrics Date: 1999-08 Impact factor: 7.124
Authors: Luis M Prieto; María Isabel González-Tomé; Eloy Muñoz; María Fernández-Ibieta; Beatriz Soto; Ana Álvarez; Maria Luisa Navarro; Miguel Ángel Roa; José Beceiro; María Isabel de José; Iciar Olabarrieta; David Lora; José Tomás Ramos Journal: BMC Infect Dis Date: 2014-12-24 Impact factor: 3.090